Home
NewsNewsNexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, has announced a strategic investment in May Health, a medical device company. This partnership aims to advance a pioneering treatment for PCOS-Related Infertility, addressing a significant gap in women's health. Nexpring Health joined a €10 million ($11.7M) financing round alongside other key investors, including Sofinnova Partners, Trill Impact, and Bpifrance.
Polycystic ovary syndrome (PCOS) is a widespread endocrine condition affecting approximately 10–13% of reproductive-aged women worldwide. It stands as a primary cause of female infertility, as the condition often prevents consistent ovulation. For many patients, the struggle to conceive is a defining challenge, leading to a critical need for innovative solutions to manage PCOS-Related Infertility.
May Health’s breakthrough technology, the Anavi™ System, offers a novel approach to this issue. It is designed as a one-time, office-based procedure intended to restore ovulation in women who have not responded to or are unable to use traditional first-line therapies. The system has already reached significant milestones, receiving CE Mark certification in October 2025. Currently, May Health is advancing its pivotal U.S. Investigational Device Exemption (IDE) trial, known as the REBALANCE study, as it seeks FDA marketing authorisation. The REBALANCE trial is a multicentre, randomised controlled study currently enrolling participants at over 15 fertility centres across the United States.
Wil Boren, CEO of Nexpring Health, emphasised that the investment reflects the company’s commitment to redefining fertility care and supporting innovations that change patient outcomes. Boren stated that May Health’s work helps move the entire field forward by expanding clinical options for both professionals and patients. Colby Holtshouse, President and CEO of May Health, added that women have long required more options to support their family-building journeys while managing PCOS-Related Infertility.
Through this collaboration, Nexpring Health continues its mission of placing clinicians and embryologists at the centre of every breakthrough. By backing the Anavi™ System, the company aims to provide reproductive medicine professionals with the tools needed to deliver consistent, confident outcomes for those hoping to start a family
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
